Ascendis Pharma A/S (NASDAQ:ASND) Given New $178.00 Price Target at Citigroup

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its price target lowered by Citigroup from $193.00 to $178.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company's stock.

Other research analysts have also issued reports about the stock. Jefferies Financial Group boosted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research note on Tuesday, August 13th. Evercore ISI raised Ascendis Pharma A/S to a strong-buy rating in a research note on Monday, August 26th. Oppenheimer upgraded shares of Ascendis Pharma A/S from a market perform rating to an outperform rating and set a $180.00 price objective on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a research note on Wednesday. Finally, StockNews.com downgraded Ascendis Pharma A/S from a hold rating to a sell rating in a research note on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of Moderate Buy and an average target price of $187.08.

Ascendis Pharma A/S Stock Down 0.4 %

ASND stock traded down $0.50 during midday trading on Wednesday, reaching $119.00. The company had a trading volume of 817,826 shares, compared to its average volume of 392,208. The stock has a 50 day moving average price of $134.73 and a 200 day moving average price of $138.46. The firm has a market capitalization of $6.93 billion, a PE ratio of -12.38 and a beta of 0.63. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently modified their holdings of ASND. Private Ocean LLC bought a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $36,000. Quadrant Capital Group LLC lifted its holdings in shares of Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 91 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock valued at $45,000 after buying an additional 102 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.